Neurodur: NEW DRUG IN THE PIPELINE
CepTor Corporation (OTC BB:CEPO), a biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, today announced that the results of Neurodur testing in the Experimental Autoimmune Encephalomyelitis (EAE) mouse model, the standard animal model used for MS testing, were published in the Journal of Neuroimmunology. The data indicated that the reduction of clinical symptoms of MS in EAE mice treated with oral Neurodur were statistically significant.

Alfred Stracher, Ph.D., Distinguished University Professor of Biochemistry at the State University of New York Downstate and co-inventor of the technology, along with Dr. Leo Kesner, Professor Emeritus, stated, "This demonstrates three very important principles: Neurodur can be readily delivered orally; it is extremely effective (p less than 0.005) in reducing MS symptoms and; represents the proof of principle as a potential therapeutic for MS." Dr. Stracher added, "We also found that Neurodur prevented demyelination (the primary cause of the symptoms of MS) and inflammatory infiltration in a dose and time-dependent manner."

The Chairman and CEO of CepTor, Bill Pursley, said, "The nice thing about the standard EAE model is that it allows you to directly address meaningful, clinical (functional) endpoints. These are exciting data in an important indication. This also demonstrates the breadth of our platform technology, cell targeted calpain inhibition, in one of several neurodegenerative diseases where the up regulation of calpain plays a key role in the pathophysiology of the disease.............."